Opiate Modulation of Feeding
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04342130|
Recruitment Status : Completed
First Posted : April 10, 2020
Last Update Posted : April 13, 2020
|Condition or disease||Intervention/treatment||Phase|
|Chronic Low-back Pain||Drug: Morphine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||9 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Opiate Modulation of Feeding|
|Actual Study Start Date :||April 27, 2018|
|Actual Primary Completion Date :||April 16, 2019|
|Actual Study Completion Date :||April 16, 2019|
Experimental: All Participants
People with low back pain who were given and oral dose of 30 mg morphine.
30 mg oral tablet
- mean change in subcortical brain structure volume [ Time Frame: baseline to 1 hour ]Magnetic Resonance Imaging (MRI) scanning was performed to collect brain volume measurements in cc.
- mean change in brain response to highly caloric drink [ Time Frame: baseline to 1 hour ]Participants received a highly caloric drink and a tasteless solution during a functional MRI scanning session. General linear model was used to generate the magnitude of the fit for each type of stimuli and differences between the fits were calculated. Next within subject analysis approach was used to calculate the effect of an acute dose of morphine on brain response to the highly caloric drink between baseline and 1 hour. The measures of the fit and their differences are expressed in z-scores.
- mean change in resting brain activity [ Time Frame: baseline to 1 hour ]Participants were scanned at rest during a functional MRI session.
- mean change in back pain intensity [ Time Frame: baseline to 1 hour ]Pain was rated using a visual analog scale ranging from 0-100 with 100 indicating the worst imaginable pain ever.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04342130
|United States, Connecticut|
|New Haven, Connecticut, United States, 06519|
|Principal Investigator:||Paul Geha, MD||Department of Psychiatry in University of Rochester|